In the article entitled “Addendum to the German Consensus Recommendations on Ponatinib in the Treatment of Chronic Myeloid Leukemia” [Acta Haematol. 2023; DOI: 10.1159/000533666] by Saussele et al., there is an error in Figure 1 which was incorrectly inserted by the authors. The correct sentence is as follows: “≤ 1% BCR::ABL1IS by 12 months” instead of “≤ 1% BCR::ABL1IS at 12 months”.

The corrected Figure 1 is shown here.

Fig. 1.

Descriptive clinical summary of response rates and AOE rates by ponatinib starting dose in the OPTIC trial (adapted from [8]). TE-AOE, treatment-emergent arterial occlusive events.

Fig. 1.

Descriptive clinical summary of response rates and AOE rates by ponatinib starting dose in the OPTIC trial (adapted from [8]). TE-AOE, treatment-emergent arterial occlusive events.

Close modal